前列腺特异抗原（PSA）检测前值和PSMA PET/CT再分期可预测生化复发前列腺癌的生存率。

Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer.

作者信息

von Eyben Rie, Hoffmann Manuela Andrea, Soydal Cigdem, Virgolini Irene, Tuncel Murat, Gauthé Mathieu, Kapp Daniel S, von Eyben Finn Edler

机构信息

Cytel Incorporated, Waltam, MA 02452, USA.

Institute for Preventive Medicine of German Armed Forces, 56626 Andernach, Germany.

出版信息

Biomedicines. 2023 Aug 22;11(9):2333. doi: 10.3390/biomedicines11092333.

DOI:10.3390/biomedicines11092333

PMID:37760775

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10525266/

Abstract

BACKGROUND

A biochemical recurrence (BCR) risk model was created based on pretest prostate specific antigen (PSA) and groupings by restaging prostate specific membrane antigen (PSMA) PET/CT.

METHODS

A cohort of 1216 BCR patients were analyzed for overall survival (OS) according to the PSA threshold and restaging PSMA PET/CT. A Cox regression analysis of OS was carried out to detect significant clinical characteristics.

RESULTS

In the cohort, 271 patients had a pretest PSA of <0.5 ng/mL and 945 patients had higher PSA values. The restaging PSMA PET/CT was positive for 834 patients and negative for 369. Of 1203 patients, 133 (11%) died, including 19 of the 369 (5%) patients without positive sites on the restaging PSMA PET/CT, 82 of the 711 (12%) with 1-5 positive sites, and 32 of the 123 (26%) with >5 positive sites. In the Cox regression analysis, four variables significantly predicted OS: treatment center, International Society of Urologic Pathology (ISUP) grade, pretest PSA threshold, and the grouping of positive sites on the restaging PSMA PET/CT.

CONCLUSIONS

The pretest PSA and PSMA PET/CT were important for the OS of the BCR patients. The findings argue for the new BCR risk model and serve as framework for ongoing trials.

摘要

背景

基于检测前前列腺特异性抗原（PSA）以及通过重新分期的前列腺特异性膜抗原（PSMA）PET/CT进行分组，创建了生化复发（BCR）风险模型。

方法

根据PSA阈值和重新分期的PSMA PET/CT，对1216例BCR患者的总生存期（OS）进行分析。对OS进行Cox回归分析以检测显著的临床特征。

结果

在该队列中，271例患者检测前PSA<0.5 ng/mL，945例患者PSA值更高。重新分期的PSMA PET/CT对834例患者呈阳性，对369例患者呈阴性。在1203例患者中，133例（11%）死亡，包括369例重新分期PSMA PET/CT无阳性部位患者中的19例（5%）、711例有1 - 5个阳性部位患者中的82例（12%）以及123例有>5个阳性部位患者中的32例（26%）。在Cox回归分析中，四个变量显著预测OS：治疗中心、国际泌尿病理学会（ISUP）分级、检测前PSA阈值以及重新分期PSMA PET/CT上阳性部位的分组。